1
Country: China | Funding: $370M
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
D3 Bio specializes in the development of innovative immunotherapies in oncology and immunology. The company's lead drug, elisrasib, is a next-generation KRAS G12C inhibitor that is being studied as a potential monotherapy for non-small cell lung cancer and metastatic colorectal cancer, as well as in combination with Merck KGaA's Erbitux anticancer drug or with immune checkpoint inhibitors. The company's pipeline includes clinical trials against mut cancers, CRC, PanCa, breast cancer, gastric cancer, bladder cancer and other solid tumors.
2
Country: USA | Funding: $280.8M
Triana Biomedicines is developing a platform to discover molecular "glues" for disease regulation. This technology identifies small molecules that facilitate interactions between two proteins (work like a glue). One such application aims to activate the innate protein degradation pathway to destroy disease-specific protein (for example in cancer cells). The company's lead candidate, TRI-611, a molecular degrader targeting ALK-positive anaplastic lymphoma kinase, is aimed at treating non-small cell lung cancer (NSCLC) and is capable of overcoming resistance observed with existing treatments. The company also has clinical trials in breast cancer in its pipeline. Pfizer is a major investor.
Triana Biomedicines is developing a platform to discover molecular "glues" for disease regulation. This technology identifies small molecules that facilitate interactions between two proteins (work like a glue). One such application aims to activate the innate protein degradation pathway to destroy disease-specific protein (for example in cancer cells). The company's lead candidate, TRI-611, a molecular degrader targeting ALK-positive anaplastic lymphoma kinase, is aimed at treating non-small cell lung cancer (NSCLC) and is capable of overcoming resistance observed with existing treatments. The company also has clinical trials in breast cancer in its pipeline. Pfizer is a major investor.
3
Country: USA | Funding: $96M
Lantern Pharma is creating the AI platform RADR for the development of oncology drugs. It's mainly used to predict the potential response of patients to drugs. RADR uses publicly available databases, commercial clinical research and trial data, proprietary company data derived from ex vivo 3D tumor transcriptome models, genomic data and drug sensitivity data from a wide range of carefully selected sources that are constantly analyzed, tracked and updated. Currently, the Lantern Pharma's portfolio includes three leading drug candidates and an ADC program for the treatment of 12 oncological diseases, including non-small cell lung cancer (NSCLC), TNBC, Bladder Cancer, Recurrent Non-Hodgkins Lymphoma, select solid tumors
Lantern Pharma is creating the AI platform RADR for the development of oncology drugs. It's mainly used to predict the potential response of patients to drugs. RADR uses publicly available databases, commercial clinical research and trial data, proprietary company data derived from ex vivo 3D tumor transcriptome models, genomic data and drug sensitivity data from a wide range of carefully selected sources that are constantly analyzed, tracked and updated. Currently, the Lantern Pharma's portfolio includes three leading drug candidates and an ADC program for the treatment of 12 oncological diseases, including non-small cell lung cancer (NSCLC), TNBC, Bladder Cancer, Recurrent Non-Hodgkins Lymphoma, select solid tumors
4
Country: Germany | Funding: $2B
BioNTech is a global leader in mRNA-based immunotherapy. The company was the first to invent and commercialize a COVID-19 vaccine (in partnership with Pfizer). BioNTech is currently developing several personalized immunotherapeutic agents (vaccines) against cancer and infectious diseases, including melanoma, human papillomavirus, non-small cell lung cancer, tuberculosis and malaria. The company's flagship platform, FixVac, enables the creation of ready-to-use mRNA cancer vaccines that can be used off-shelf to a specific indication (fixed-dose vaccines). These vaccines are a fixed combination of unmutated tumor antigens encoded by mRNA, which are frequently expressed in certain types of cancer. The mRNA is delivered using a proprietary RNA-lipoplex delivery system, which is designed to enhance mRNA stability in the body and target antigen-presenting dendritic cells (DCs), the training grounds of our immune system.
BioNTech is a global leader in mRNA-based immunotherapy. The company was the first to invent and commercialize a COVID-19 vaccine (in partnership with Pfizer). BioNTech is currently developing several personalized immunotherapeutic agents (vaccines) against cancer and infectious diseases, including melanoma, human papillomavirus, non-small cell lung cancer, tuberculosis and malaria. The company's flagship platform, FixVac, enables the creation of ready-to-use mRNA cancer vaccines that can be used off-shelf to a specific indication (fixed-dose vaccines). These vaccines are a fixed combination of unmutated tumor antigens encoded by mRNA, which are frequently expressed in certain types of cancer. The mRNA is delivered using a proprietary RNA-lipoplex delivery system, which is designed to enhance mRNA stability in the body and target antigen-presenting dendritic cells (DCs), the training grounds of our immune system.
5
Country: USA | Funding: $86.9M
Vaccinex develops novel therapeutic antibodies for treatment of neurodegenerative diseases and cancer. Its drugs are based on the inhibition of semaphorin SEMA4D - potent biological effector believed to prevent immune infiltration and induce myeloid-derived suppressor cells in tumors, as well as trigger neuroinflammation through reactive gliosis in the brain. The company's lead drug candidate, pepinemab, blocks SEMA4D and has the potential to enhance immune activity against tumors and reprogram underlying pathogenic immune mechanisms that exacerbate damage in chronic neurological diseases such as Asheimer's disease and Huntington's disease. The company is also advancing candidates for the treatment of cervical, pancreatic and lung cancer. Vaccinex uses its proprietary ActivMAb drug discovery platform, which enables the discovery and development of highly selective antibodies with novel mechanisms of action against complex membrane proteins.
Vaccinex develops novel therapeutic antibodies for treatment of neurodegenerative diseases and cancer. Its drugs are based on the inhibition of semaphorin SEMA4D - potent biological effector believed to prevent immune infiltration and induce myeloid-derived suppressor cells in tumors, as well as trigger neuroinflammation through reactive gliosis in the brain. The company's lead drug candidate, pepinemab, blocks SEMA4D and has the potential to enhance immune activity against tumors and reprogram underlying pathogenic immune mechanisms that exacerbate damage in chronic neurological diseases such as Asheimer's disease and Huntington's disease. The company is also advancing candidates for the treatment of cervical, pancreatic and lung cancer. Vaccinex uses its proprietary ActivMAb drug discovery platform, which enables the discovery and development of highly selective antibodies with novel mechanisms of action against complex membrane proteins.
6
Country: USA | Funding: $3.9B
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
Moderna is a pioneer in developing a new class of drugs based on messenger RNA (mRNA). This new drug platform is based on the discovery that in-vitro engeneered and injected mRNA can direct the body's cellular machinery to produce virtually any protein of interest, from native proteins to antibodies and other entirely new protein constructs with therapeutic activity both inside and outside cells. In other words, mRNA can guide the body to produce its own drugs. Moderna used mRNA to create the first COVID-19 vaccine and is now applying this technology to create vaccines for infectious diseases (influenza, RSV, HSV, etc.), immuno-oncology (melanoma, lung cancer, liver cancer, etc.), rare diseases and autoimmune diseases.
7
Country: USA | Funding: $1.6B
IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL)
IOVANCE Biotherapeutics is focused on the development and commercialization of autologous cellular immunotherapies optimizing personalized, tumor-directed Tumor Infiltrating Lymphocytes (TIL)
8
Country: USA | Funding: $1.3B
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.
9
Country: USA | Funding: $1.3B
Fate Therapeutics develops clinical drug candidates for the treatment of autoimmune diseases and cancer using its propriety iPSCs platform (induced pluripotent stem cells). These cell therapies are selectively engineered and provide novel synthetic mechanisms for regulating cellular function. The company utilizes iPSC master cell lines to generate immune system cells, including NK cells, T cells and CD34+ cells and is developing a portfolio of ready-to-use cellular immunotherapy products for the treatment of solid tumors (particularly lung, pancreatic and ovarian cancer). FT819, its first iPSC-derived CAR T-cell product candidate, demonstrates potent, dose-dependent B-cell killing comparable to that of autologous primary CAR T cells in in-vitro cytotoxicity assay using peripheral blood mononuclear cells (PBMCs) in SLE.
Fate Therapeutics develops clinical drug candidates for the treatment of autoimmune diseases and cancer using its propriety iPSCs platform (induced pluripotent stem cells). These cell therapies are selectively engineered and provide novel synthetic mechanisms for regulating cellular function. The company utilizes iPSC master cell lines to generate immune system cells, including NK cells, T cells and CD34+ cells and is developing a portfolio of ready-to-use cellular immunotherapy products for the treatment of solid tumors (particularly lung, pancreatic and ovarian cancer). FT819, its first iPSC-derived CAR T-cell product candidate, demonstrates potent, dose-dependent B-cell killing comparable to that of autologous primary CAR T cells in in-vitro cytotoxicity assay using peripheral blood mononuclear cells (PBMCs) in SLE.
10
Country: Israel | Funding: $1B
Novocure is developing a new treatment for solid tumors known as tumor polytherapy (TTFields). TTFields are low-intensity alternating electric fields, particularly at intermediate frequencies that disrupt cancer cell division through physical interaction with key molecules during mitosis. TTFields do significantly affect healthy cells, as they have different properties (including division rate, morphology and electrical properties) compared to cancer cells. The company's TTFields pipeline includes therapies against glioblastoma, metastatic non-small cell lung cancer and pancreatic cancer. The company also produces FDA-approved portable devices for the treatment of GB and mNSCLC. These devices also work via creating electric fields that can slow or stop cancer cell division.
Novocure is developing a new treatment for solid tumors known as tumor polytherapy (TTFields). TTFields are low-intensity alternating electric fields, particularly at intermediate frequencies that disrupt cancer cell division through physical interaction with key molecules during mitosis. TTFields do significantly affect healthy cells, as they have different properties (including division rate, morphology and electrical properties) compared to cancer cells. The company's TTFields pipeline includes therapies against glioblastoma, metastatic non-small cell lung cancer and pancreatic cancer. The company also produces FDA-approved portable devices for the treatment of GB and mNSCLC. These devices also work via creating electric fields that can slow or stop cancer cell division.
11
Country: USA | Funding: $337M
Alaunos Therapeutics develops immunotherapies for cancer treatment using novel TCR-derived T cells. These cell therapies target neoantigens (neoAgs) arising from genomic mutations in solid tumors. The company has developed proprietary, rapid and cost-effective solutions for the delivery of tumor-specific killer T cells. Alaunos' clinical TCR library targets the most common mutations in the KRAS, TP53 and EGFR genes, which are prevalent in gastrointestinal (colon, bile duct, pancreatic), lung and gynecologic (ovarian and endometrial) cancers across a range of different HLA alleles. Company's propriety non-viral Sleeping Beauty transposon/transposase system is used to introduce the TCR gene into the patient's autologous T cells. Alaunos's current pipeline includes clinical trials against lung, colorectal, pancreatic and ovarian cancers.
Alaunos Therapeutics develops immunotherapies for cancer treatment using novel TCR-derived T cells. These cell therapies target neoantigens (neoAgs) arising from genomic mutations in solid tumors. The company has developed proprietary, rapid and cost-effective solutions for the delivery of tumor-specific killer T cells. Alaunos' clinical TCR library targets the most common mutations in the KRAS, TP53 and EGFR genes, which are prevalent in gastrointestinal (colon, bile duct, pancreatic), lung and gynecologic (ovarian and endometrial) cancers across a range of different HLA alleles. Company's propriety non-viral Sleeping Beauty transposon/transposase system is used to introduce the TCR gene into the patient's autologous T cells. Alaunos's current pipeline includes clinical trials against lung, colorectal, pancreatic and ovarian cancers.
12
Country: USA | Funding: $325M
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.
13
Country: USA | Funding: $313M
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
Bicara Therapeutics develops dual-action cancer therapies, combining targeted treatments with tumor modulators for enhanced impact.
14
Country: USA | Funding: $177M
Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.
Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.
15
Country: Denmark | Funding: $160.4M
Galecto develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer. The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto Biotech a unique platform.
Galecto develops galectin modulators for the treatment of severe diseases, including fibrosis and cancer. The company builds on more than 10 years of research into galectins and galectin modulators, which combined with a strong patent estate gives Galecto Biotech a unique platform.
16
Country: USA | Funding: $112.3M
iMDx is focused on cancers with large patient populations and significant unmet need. The company is developing three genetic tests – blood tests for breast cancer and lung cancer, and a urine-based test for bladder cancer.
iMDx is focused on cancers with large patient populations and significant unmet need. The company is developing three genetic tests – blood tests for breast cancer and lung cancer, and a urine-based test for bladder cancer.
17
Country: USA | Funding: $106M
Totus Medicines is a provider of chemical biology technologies by creating life-changing covalent drugs.
Totus Medicines is a provider of chemical biology technologies by creating life-changing covalent drugs.
18
Country: China | Funding: $101.6M
Juventas is a provider and developer of innovative immune cell therapeutic drugs.
Juventas is a provider and developer of innovative immune cell therapeutic drugs.
19
Country: USA | Funding: $95.5M
Genprex is a clinical stage gene therapy company developing molecular therapies to better target lung cancer cells. Their new approach to treating cancer is based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex immunogene therapy, or Oncoprex.
Genprex is a clinical stage gene therapy company developing molecular therapies to better target lung cancer cells. Their new approach to treating cancer is based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex immunogene therapy, or Oncoprex.
20
Country: USA | Funding: $82.4M
Rain Therapeutics is a biotech company laser focused on a subtype of non-small cell lung cancer
Rain Therapeutics is a biotech company laser focused on a subtype of non-small cell lung cancer
